- Home
- SD vs GLUE Comparison
SD vs GLUE Comparison
Compare SD & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- GLUE
- Stock Information
- Founded
- SD 2006
- GLUE 2019
- Country
- SD United States
- GLUE United States
- Employees
- SD N/A
- GLUE N/A
- Industry
- SD Oil & Gas Production
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- GLUE Health Care
- Exchange
- SD Nasdaq
- GLUE Nasdaq
- Market Cap
- SD 420.5M
- GLUE 475.5M
- IPO Year
- SD 2007
- GLUE 2021
- Fundamental
- Price
- SD $10.55
- GLUE $6.93
- Analyst Decision
- SD
- GLUE Buy
- Analyst Count
- SD 0
- GLUE 3
- Target Price
- SD N/A
- GLUE $12.67
- AVG Volume (30 Days)
- SD 332.6K
- GLUE 1.8M
- Earning Date
- SD 11-06-2024
- GLUE 11-07-2024
- Dividend Yield
- SD 4.18%
- GLUE N/A
- EPS Growth
- SD N/A
- GLUE N/A
- EPS
- SD 1.27
- GLUE N/A
- Revenue
- SD $120,243,000.00
- GLUE $14,975,000.00
- Revenue This Year
- SD N/A
- GLUE N/A
- Revenue Next Year
- SD $43.19
- GLUE N/A
- P/E Ratio
- SD $8.29
- GLUE N/A
- Revenue Growth
- SD N/A
- GLUE N/A
- 52 Week Low
- SD $10.31
- GLUE $3.21
- 52 Week High
- SD $15.31
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- SD 32.11
- GLUE 39.61
- Support Level
- SD $10.31
- GLUE $6.15
- Resistance Level
- SD $11.10
- GLUE $7.95
- Average True Range (ATR)
- SD 0.32
- GLUE 0.88
- MACD
- SD -0.09
- GLUE -0.34
- Stochastic Oscillator
- SD 16.22
- GLUE 17.18
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.